ResMed Inc.

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, RMD is priced at $204.15, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, RMD's ROE is +0.24%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSX-PA's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ISRG has a market cap of 155.8B. Regarding current trading prices, RMD is priced at $204.15, while ISRG trades at $439.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ISRG's P/E ratio is 53.58. In terms of profitability, RMD's ROE is +0.24%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ABT has a market cap of 153.1B. Regarding current trading prices, RMD is priced at $204.15, while ABT trades at $87.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ABT's P/E ratio is 24.61. In terms of profitability, RMD's ROE is +0.24%, compared to ABT's ROE of +0.12%. Regarding short-term risk, RMD is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ABT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SYK has a market cap of 120.1B. Regarding current trading prices, RMD is priced at $204.15, while SYK trades at $313.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SYK's P/E ratio is 36.22. In terms of profitability, RMD's ROE is +0.24%, compared to SYK's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SYK's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, MDT has a market cap of 99.3B. Regarding current trading prices, RMD is priced at $204.15, while MDT trades at $77.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas MDT's P/E ratio is 21.59. In terms of profitability, RMD's ROE is +0.24%, compared to MDT's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MDT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BSX has a market cap of 83.2B. Regarding current trading prices, RMD is priced at $204.15, while BSX trades at $55.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BSX's P/E ratio is 23.41. In terms of profitability, RMD's ROE is +0.24%, compared to BSX's ROE of +0.15%. Regarding short-term risk, RMD is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BRKRP has a market cap of 50.1B. Regarding current trading prices, RMD is priced at $204.15, while BRKRP trades at $332.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BRKRP's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BRKRP's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, EW has a market cap of 47.4B. Regarding current trading prices, RMD is priced at $204.15, while EW trades at $82.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas EW's P/E ratio is 44.53. In terms of profitability, RMD's ROE is +0.24%, compared to EW's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EW's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, DXCM has a market cap of 25.1B. Regarding current trading prices, RMD is priced at $204.15, while DXCM trades at $65.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas DXCM's P/E ratio is 27.94. In terms of profitability, RMD's ROE is +0.24%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, RMD is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DXCM's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PHG has a market cap of 24.8B. Regarding current trading prices, RMD is priced at $204.15, while PHG trades at $26.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PHG's P/E ratio is 22.26. In terms of profitability, RMD's ROE is +0.24%, compared to PHG's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PHG's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, STE has a market cap of 20.9B. Regarding current trading prices, RMD is priced at $204.15, while STE trades at $212.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas STE's P/E ratio is 26.86. In terms of profitability, RMD's ROE is +0.24%, compared to STE's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check STE's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, RMD is priced at $204.15, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ABMD's P/E ratio is 65.36. In terms of profitability, RMD's ROE is +0.24%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, RMD is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ABMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ZBH has a market cap of 16.5B. Regarding current trading prices, RMD is priced at $204.15, while ZBH trades at $85.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ZBH's P/E ratio is 22.05. In terms of profitability, RMD's ROE is +0.24%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, RMD is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ZBH's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, RMD is priced at $204.15, while SNN trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SNN's P/E ratio is 21.19. In terms of profitability, RMD's ROE is +0.24%, compared to SNN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SNN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, RMD is priced at $204.15, while PEN trades at $326.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PEN's P/E ratio is 75.09. In terms of profitability, RMD's ROE is +0.24%, compared to PEN's ROE of +0.12%. Regarding short-term risk, RMD is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check PEN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, RMD is priced at $204.15, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SWAV's P/E ratio is 78.76. In terms of profitability, RMD's ROE is +0.24%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, RMD is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SWAV's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ALGN has a market cap of 11.4B. Regarding current trading prices, RMD is priced at $204.15, while ALGN trades at $158.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ALGN's P/E ratio is 26.73. In terms of profitability, RMD's ROE is +0.24%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ALGN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, GMED has a market cap of 10.6B. Regarding current trading prices, RMD is priced at $204.15, while GMED trades at $78.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas GMED's P/E ratio is 18.44. In terms of profitability, RMD's ROE is +0.24%, compared to GMED's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GMED's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PODD has a market cap of 10.6B. Regarding current trading prices, RMD is priced at $204.15, while PODD trades at $152.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PODD's P/E ratio is 35.71. In terms of profitability, RMD's ROE is +0.24%, compared to PODD's ROE of +0.21%. Regarding short-term risk, RMD is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PODD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, RMD is priced at $204.15, while MASI trades at $178.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas MASI's P/E ratio is 44.37. In terms of profitability, RMD's ROE is +0.24%, compared to MASI's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MASI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, GKOS has a market cap of 8.3B. Regarding current trading prices, RMD is priced at $204.15, while GKOS trades at $142.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas GKOS's P/E ratio is -43.07. In terms of profitability, RMD's ROE is +0.24%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check GKOS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, RMD is priced at $204.15, while BIO trades at $281.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BIO's P/E ratio is 46.91. In terms of profitability, RMD's ROE is +0.24%, compared to BIO's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BIO's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, RMD is priced at $204.15, while BIO-B trades at $267.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BIO-B's P/E ratio is 46.95. In terms of profitability, RMD's ROE is +0.24%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, RMD is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check BIO-B's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BRKR has a market cap of 6.5B. Regarding current trading prices, RMD is priced at $204.15, while BRKR trades at $42.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BRKR's P/E ratio is -178.12. In terms of profitability, RMD's ROE is +0.24%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, RMD is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BRKR's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, RMD is priced at $204.15, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas NARI's P/E ratio is -59.24. In terms of profitability, RMD's ROE is +0.24%, compared to NARI's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NARI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, RMD is priced at $204.15, while LIVN trades at $72.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas LIVN's P/E ratio is 36.85. In terms of profitability, RMD's ROE is +0.24%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, RMD is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LIVN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, RMD is priced at $204.15, while IRTC trades at $110.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas IRTC's P/E ratio is -129.00. In terms of profitability, RMD's ROE is +0.24%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRTC's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, RMD is priced at $204.15, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AXNX's P/E ratio is -709.80. In terms of profitability, RMD's ROE is +0.24%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, RMD is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AXNX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, RMD is priced at $204.15, while ITGR trades at $89.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ITGR's P/E ratio is 22.33. In terms of profitability, RMD's ROE is +0.24%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, RMD is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ITGR's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, TMDX has a market cap of 2.4B. Regarding current trading prices, RMD is priced at $204.15, while TMDX trades at $68.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas TMDX's P/E ratio is 15.64. In terms of profitability, RMD's ROE is +0.24%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, RMD is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMDX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, RMD is priced at $204.15, while AXGN trades at $41.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AXGN's P/E ratio is -65.55. In terms of profitability, RMD's ROE is +0.24%, compared to AXGN's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AXGN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, RMD is priced at $204.15, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas NUVA's P/E ratio is 75.00. In terms of profitability, RMD's ROE is +0.24%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NUVA's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, RMD is priced at $204.15, while ESTA trades at $65.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ESTA's P/E ratio is -44.65. In terms of profitability, RMD's ROE is +0.24%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, RMD is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ESTA's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, RMD is priced at $204.15, while UFPT trades at $217.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas UFPT's P/E ratio is 24.77. In terms of profitability, RMD's ROE is +0.24%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, RMD is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check UFPT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $204.15, while PRCT trades at $26.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PRCT's P/E ratio is -14.21. In terms of profitability, RMD's ROE is +0.24%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, RMD is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PRCT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AHCO has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $204.15, while AHCO trades at $10.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AHCO's P/E ratio is -18.17. In terms of profitability, RMD's ROE is +0.24%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, RMD is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AHCO's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $204.15, while ENOV trades at $25.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ENOV's P/E ratio is -1.27. In terms of profitability, RMD's ROE is +0.24%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, RMD is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ENOV's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, RMD is priced at $204.15, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas HSKA's P/E ratio is -62.49. In terms of profitability, RMD's ROE is +0.24%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check HSKA's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $204.15, while ATEC trades at $8.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ATEC's P/E ratio is -9.75. In terms of profitability, RMD's ROE is +0.24%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, RMD is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ATEC's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $204.15, while INSP trades at $41.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas INSP's P/E ratio is 9.50. In terms of profitability, RMD's ROE is +0.24%, compared to INSP's ROE of +0.18%. Regarding short-term risk, RMD is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INSP's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $204.15, while AVNS trades at $24.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AVNS's P/E ratio is -15.45. In terms of profitability, RMD's ROE is +0.24%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, RMD is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check AVNS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AORT has a market cap of 1.2B. Regarding current trading prices, RMD is priced at $204.15, while AORT trades at $23.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AORT's P/E ratio is 95.04. In terms of profitability, RMD's ROE is +0.24%, compared to AORT's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AORT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $204.15, while IRMD trades at $88.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas IRMD's P/E ratio is 48.36. In terms of profitability, RMD's ROE is +0.24%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, RMD is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IRMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $204.15, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SILK's P/E ratio is -18.96. In terms of profitability, RMD's ROE is +0.24%, compared to SILK's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SILK's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $204.15, while CNMD trades at $36.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CNMD's P/E ratio is 20.67. In terms of profitability, RMD's ROE is +0.24%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CNMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $204.15, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas FNA's P/E ratio is -19.83. In terms of profitability, RMD's ROE is +0.24%, compared to FNA's ROE of -0.35%. Regarding short-term risk, RMD is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check FNA's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $204.15, while IART trades at $14.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas IART's P/E ratio is -2.18. In terms of profitability, RMD's ROE is +0.24%, compared to IART's ROE of -0.48%. Regarding short-term risk, RMD is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check IART's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, RMD is priced at $204.15, while BFLY trades at $3.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BFLY's P/E ratio is -12.82. In terms of profitability, RMD's ROE is +0.24%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BFLY's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, TNDM has a market cap of 927.2M. Regarding current trading prices, RMD is priced at $204.15, while TNDM trades at $13.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas TNDM's P/E ratio is -9.88. In terms of profitability, RMD's ROE is +0.24%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, RMD is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TNDM's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, INMD has a market cap of 893.4M. Regarding current trading prices, RMD is priced at $204.15, while INMD trades at $14.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas INMD's P/E ratio is 10.44. In terms of profitability, RMD's ROE is +0.24%, compared to INMD's ROE of +0.13%. Regarding short-term risk, RMD is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check INMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, RMD is priced at $204.15, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CSII's P/E ratio is -20.83. In terms of profitability, RMD's ROE is +0.24%, compared to CSII's ROE of -0.14%. Regarding short-term risk, RMD is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check CSII's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SSII has a market cap of 796.5M. Regarding current trading prices, RMD is priced at $204.15, while SSII trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SSII's P/E ratio is -79.60. In terms of profitability, RMD's ROE is +0.24%, compared to SSII's ROE of -0.23%. Regarding short-term risk, RMD is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SSII's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, RMD is priced at $204.15, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CRY's P/E ratio is 425.71. In terms of profitability, RMD's ROE is +0.24%, compared to CRY's ROE of +0.03%. Regarding short-term risk, RMD is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CRY's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BVS has a market cap of 720.2M. Regarding current trading prices, RMD is priced at $204.15, while BVS trades at $10.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BVS's P/E ratio is 25.93. In terms of profitability, RMD's ROE is +0.24%, compared to BVS's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BVS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SIBN has a market cap of 654.6M. Regarding current trading prices, RMD is priced at $204.15, while SIBN trades at $14.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SIBN's P/E ratio is -37.85. In terms of profitability, RMD's ROE is +0.24%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, RMD is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SIBN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, LMRI has a market cap of 650.7M. Regarding current trading prices, RMD is priced at $204.15, while LMRI trades at $6.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas LMRI's P/E ratio is -17.36. In terms of profitability, RMD's ROE is +0.24%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LMRI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CBLL has a market cap of 629.1M. Regarding current trading prices, RMD is priced at $204.15, while CBLL trades at $16.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CBLL's P/E ratio is -10.23. In terms of profitability, RMD's ROE is +0.24%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, RMD is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CBLL's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, RMD is priced at $204.15, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SRDX's P/E ratio is -34.66. In terms of profitability, RMD's ROE is +0.24%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, RMD is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SRDX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BWAY has a market cap of 583.6M. Regarding current trading prices, RMD is priced at $204.15, while BWAY trades at $14.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BWAY's P/E ratio is 82.67. In terms of profitability, RMD's ROE is +0.24%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BWAY's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, RMD is priced at $204.15, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas APEN's P/E ratio is -9.43. In terms of profitability, RMD's ROE is +0.24%, compared to APEN's ROE of -0.85%. Regarding short-term risk, RMD is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check APEN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, NPCE has a market cap of 545.2M. Regarding current trading prices, RMD is priced at $204.15, while NPCE trades at $15.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas NPCE's P/E ratio is -24.60. In terms of profitability, RMD's ROE is +0.24%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check NPCE's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, RMD is priced at $204.15, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, RMD's ROE is +0.24%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, RMD is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check ZIMV's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, TCMD has a market cap of 533.5M. Regarding current trading prices, RMD is priced at $204.15, while TCMD trades at $23.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas TCMD's P/E ratio is 27.18. In terms of profitability, RMD's ROE is +0.24%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, RMD is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TCMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, OFIX has a market cap of 490.7M. Regarding current trading prices, RMD is priced at $204.15, while OFIX trades at $12.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas OFIX's P/E ratio is -8.09. In terms of profitability, RMD's ROE is +0.24%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check OFIX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CERS has a market cap of 486.9M. Regarding current trading prices, RMD is priced at $204.15, while CERS trades at $2.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CERS's P/E ratio is -48.60. In terms of profitability, RMD's ROE is +0.24%, compared to CERS's ROE of -0.15%. Regarding short-term risk, RMD is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CERS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, KIDS has a market cap of 465.9M. Regarding current trading prices, RMD is priced at $204.15, while KIDS trades at $18.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas KIDS's P/E ratio is -10.80. In terms of profitability, RMD's ROE is +0.24%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, RMD is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check KIDS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CTKB has a market cap of 458.5M. Regarding current trading prices, RMD is priced at $204.15, while CTKB trades at $3.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CTKB's P/E ratio is -6.12. In terms of profitability, RMD's ROE is +0.24%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CTKB's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, VREX has a market cap of 408.4M. Regarding current trading prices, RMD is priced at $204.15, while VREX trades at $9.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas VREX's P/E ratio is -4.85. In terms of profitability, RMD's ROE is +0.24%, compared to VREX's ROE of -0.18%. Regarding short-term risk, RMD is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check VREX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, LAB has a market cap of 386.1M. Regarding current trading prices, RMD is priced at $204.15, while LAB trades at $0.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas LAB's P/E ratio is -7.61. In terms of profitability, RMD's ROE is +0.24%, compared to LAB's ROE of -0.21%. Regarding short-term risk, RMD is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check LAB's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, DCTH has a market cap of 382.8M. Regarding current trading prices, RMD is priced at $204.15, while DCTH trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas DCTH's P/E ratio is 1109.00. In terms of profitability, RMD's ROE is +0.24%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, RMD is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check DCTH's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, VMD has a market cap of 369.6M. Regarding current trading prices, RMD is priced at $204.15, while VMD trades at $9.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas VMD's P/E ratio is 26.05. In terms of profitability, RMD's ROE is +0.24%, compared to VMD's ROE of +0.11%. Regarding short-term risk, RMD is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check VMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PACB has a market cap of 357.2M. Regarding current trading prices, RMD is priced at $204.15, while PACB trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PACB's P/E ratio is -2.80. In terms of profitability, RMD's ROE is +0.24%, compared to PACB's ROE of -4.88%. Regarding short-term risk, RMD is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PACB's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CLPT has a market cap of 333.8M. Regarding current trading prices, RMD is priced at $204.15, while CLPT trades at $11.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CLPT's P/E ratio is -11.13. In terms of profitability, RMD's ROE is +0.24%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, RMD is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CLPT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ELMD has a market cap of 316.7M. Regarding current trading prices, RMD is priced at $204.15, while ELMD trades at $38.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ELMD's P/E ratio is 32.69. In terms of profitability, RMD's ROE is +0.24%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, RMD is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ELMD's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, RMD is priced at $204.15, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SMLR's P/E ratio is 3.92. In terms of profitability, RMD's ROE is +0.24%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, RMD is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check SMLR's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CATX has a market cap of 291.2M. Regarding current trading prices, RMD is priced at $204.15, while CATX trades at $3.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CATX's P/E ratio is -2.67. In terms of profitability, RMD's ROE is +0.24%, compared to CATX's ROE of -0.42%. Regarding short-term risk, RMD is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CATX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, AVR has a market cap of 278.5M. Regarding current trading prices, RMD is priced at $204.15, while AVR trades at $7.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas AVR's P/E ratio is -3.41. In terms of profitability, RMD's ROE is +0.24%, compared to AVR's ROE of -1.24%. Regarding short-term risk, RMD is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check AVR's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PMI has a market cap of 266.8M. Regarding current trading prices, RMD is priced at $204.15, while PMI trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PMI's P/E ratio is -0.23. In terms of profitability, RMD's ROE is +0.24%, compared to PMI's ROE of +4.99%. Regarding short-term risk, RMD is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PMI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SGHT has a market cap of 264.4M. Regarding current trading prices, RMD is priced at $204.15, while SGHT trades at $4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SGHT's P/E ratio is -6.94. In terms of profitability, RMD's ROE is +0.24%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, RMD is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SGHT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, MASS has a market cap of 251.1M. Regarding current trading prices, RMD is priced at $204.15, while MASS trades at $6.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas MASS's P/E ratio is -6.85. In terms of profitability, RMD's ROE is +0.24%, compared to MASS's ROE of -0.26%. Regarding short-term risk, RMD is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MASS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, RXST has a market cap of 248.4M. Regarding current trading prices, RMD is priced at $204.15, while RXST trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas RXST's P/E ratio is -5.31. In terms of profitability, RMD's ROE is +0.24%, compared to RXST's ROE of -0.17%. Regarding short-term risk, RMD is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check RXST's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, RMD is priced at $204.15, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas MGRM's P/E ratio is -11.11. In terms of profitability, RMD's ROE is +0.24%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, RMD is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check MGRM's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SENS has a market cap of 232.4M. Regarding current trading prices, RMD is priced at $204.15, while SENS trades at $5.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SENS's P/E ratio is -2.82. In terms of profitability, RMD's ROE is +0.24%, compared to SENS's ROE of -1.30%. Regarding short-term risk, RMD is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SENS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, RMD is priced at $204.15, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas NVRO's P/E ratio is -1.91. In terms of profitability, RMD's ROE is +0.24%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check NVRO's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, RMD is priced at $204.15, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas EYES's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to EYES's ROE of -2.64%. Regarding short-term risk, RMD is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EYES's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, PROF has a market cap of 208.5M. Regarding current trading prices, RMD is priced at $204.15, while PROF trades at $6.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas PROF's P/E ratio is -5.56. In terms of profitability, RMD's ROE is +0.24%, compared to PROF's ROE of -0.71%. Regarding short-term risk, RMD is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check PROF's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, ANIK has a market cap of 198.9M. Regarding current trading prices, RMD is priced at $204.15, while ANIK trades at $14.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas ANIK's P/E ratio is -18.92. In terms of profitability, RMD's ROE is +0.24%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check ANIK's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, RMD is priced at $204.15, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas BSGM's P/E ratio is -5.81. In terms of profitability, RMD's ROE is +0.24%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, RMD is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check BSGM's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, RMD is priced at $204.15, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas MDGS's P/E ratio is -0.27. In terms of profitability, RMD's ROE is +0.24%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, RMD is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check MDGS's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, TMCI has a market cap of 178.4M. Regarding current trading prices, RMD is priced at $204.15, while TMCI trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas TMCI's P/E ratio is -2.86. In terms of profitability, RMD's ROE is +0.24%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, RMD is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check TMCI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, INGN has a market cap of 170.6M. Regarding current trading prices, RMD is priced at $204.15, while INGN trades at $6.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas INGN's P/E ratio is -6.92. In terms of profitability, RMD's ROE is +0.24%, compared to INGN's ROE of -0.13%. Regarding short-term risk, RMD is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check INGN's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, EDAP has a market cap of 167.9M. Regarding current trading prices, RMD is priced at $204.15, while EDAP trades at $4.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas EDAP's P/E ratio is -5.46. In terms of profitability, RMD's ROE is +0.24%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, RMD is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check EDAP's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, RMD is priced at $204.15, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas QIPT's P/E ratio is -15.87. In terms of profitability, RMD's ROE is +0.24%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for RMD.Check QIPT's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, APYX has a market cap of 162.1M. Regarding current trading prices, RMD is priced at $204.15, while APYX trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas APYX's P/E ratio is -17.59. In terms of profitability, RMD's ROE is +0.24%, compared to APYX's ROE of -0.91%. Regarding short-term risk, RMD is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check APYX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, CVRX has a market cap of 157M. Regarding current trading prices, RMD is priced at $204.15, while CVRX trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas CVRX's P/E ratio is -2.96. In terms of profitability, RMD's ROE is +0.24%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, RMD is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check CVRX's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, QTI has a market cap of 149M. Regarding current trading prices, RMD is priced at $204.15, while QTI trades at $5.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas QTI's P/E ratio is -2.73. In terms of profitability, RMD's ROE is +0.24%, compared to QTI's ROE of -63.30%. Regarding short-term risk, RMD is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QTI's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, SNWV has a market cap of 145M. Regarding current trading prices, RMD is priced at $204.15, while SNWV trades at $16.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas SNWV's P/E ratio is 17.56. In terms of profitability, RMD's ROE is +0.24%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, RMD is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check SNWV's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, HYPR has a market cap of 121M. Regarding current trading prices, RMD is priced at $204.15, while HYPR trades at $1.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas HYPR's P/E ratio is -3.62. In terms of profitability, RMD's ROE is +0.24%, compared to HYPR's ROE of -1.01%. Regarding short-term risk, RMD is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check HYPR's competition here

RMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, RMD stands at 29.6B. In comparison, QTRX has a market cap of 118.7M. Regarding current trading prices, RMD is priced at $204.15, while QTRX trades at $2.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

RMD currently has a P/E ratio of 19.67, whereas QTRX's P/E ratio is -1.07. In terms of profitability, RMD's ROE is +0.24%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, RMD is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for RMD.Check QTRX's competition here